🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSUSTAIN-6 to SELECT — what worked for you? Page 8

SUSTAIN-6 to SELECT — what worked for you?

fiona_VT Sat, Aug 16, 2025 at 4:04 PM 38 replies 1,492 viewsPage 8 of 8
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Feb 25, 2026 at 8:12 AM#36
traveltech_sara said:
I want to bring up the cardiovascular angle on cardiovascular risk.

Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

The 5 criteria (and my journey):

  1. Waist circumference: 49" → 37" ✅ Resolved
  2. Triglycerides: 263 → 118 ✅ Resolved
  3. HDL: 33 → 55 ✅ Resolved
  4. Blood pressure: 143/97 → 121/75 ✅ Resolved
  5. Fasting glucose: 128 → 85 ✅ Resolved

Metabolic syndrome reversal is, in my view, the most medically significant outcome of GLP-1 therapy.

Last edited: Feb 25, 2026 at 12:12 PM
10 8sarah_nash92, FitDadDave, RunnerRach and 7 others
Reply Quote Save Share Report
MikeKY_noInsulin
Member
267
1,234
Oct 2024
Louisville, KY
Mar 8, 2026 at 2:38 AM#37

Following on from traveltech_sara — and this may be the naive question:

Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?

11 9hannah_MT, Dr.SportsMedIN, amy_econ_NJ and 8 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Mar 18, 2026 at 8:58 PM#38
bri_stats said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

NNT calculation for cardiovascular risk clinical endpoints: NNT = 1/ARR (absolute risk reduction).

From SELECT trial: MACE at 39 months — 6.5% semaglutide vs 8.0% placebo. ARR = 1.5%. NNT = 67 over 3.3 years.

Compare to established therapies:

InterventionNNTTimeframe
Semaglutide (MACE)673.3 years
Statins primary prevention (MI)~1005 years
Aspirin secondary prevention~772 years

These NNTs are clinically meaningful and comparable to accepted cardiovascular interventions.

12 10SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 9 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Mar 29, 2026 at 3:12 PM#39
bri_stats said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

Mendelian randomization evidence supporting GLP-1 pathway modulation for cardiovascular risk: genetic variants in the GLP1R gene region associated with lower BMI also show associations with reduced cardiovascular risk, confirming a causal pathway[1].

This "natural experiment" (people born with genetically higher GLP-1 signaling being leaner and healthier) provides orthogonal evidence supporting the pharmacological approach. When genetic epidemiology, clinical trials, and mechanistic studies all converge, confidence in the therapeutic approach is high.

References:
[1] Zheng SL, et al. Lancet Diabetes Endocrinol. 2023;11(12):869-879.
13 11RegAffairsDC, BiostatsBrad, PeptideSynthNJ and 10 others
Reply Quote Save Share Report
mike_nyc
VIP Member
5,678
21,345
Nov 2023
New York
Online
Apr 9, 2026 at 9:20 AM#40
bri_stats said:
Metabolic syndrome resolution on cardiovascular risk: I went from meeting 5 of 5 diagnostic criteria to meeting ZERO after 10 months of treatment.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

Last edited: Apr 9, 2026 at 1:20 PM
35 8CarlaRPh_TPA, steph_laguna, fiona_glasgow and 32 others
Reply Quote Save Share Report
1678

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register